NEW BRUNSWICK, N.J.,
Oct. 17, 2017 /PRNewswire/
-- Johnson & Johnson (NYSE: JNJ) today announced sales of
$19.7 billion for the third quarter
of 2017, an increase of 10.3% as compared to the third quarter of
2016. Operational sales results increased 9.5% and the positive
impact of currency was 0.8%. Domestic sales increased 9.7%.
International sales increased 10.9%, reflecting operational growth
of 9.3% and a positive currency impact of 1.6%. Excluding the net
impact of acquisitions and divestitures, on an operational basis,
worldwide, domestic and international sales each increased
3.8%.*
Net earnings and diluted earnings per share for the third
quarter of 2017 were $3.8 billion and
$1.37, respectively. Third-quarter
2017 net earnings included after-tax intangible amortization
expense of approximately $0.9 billion
and a charge for after-tax special items of approximately
$0.5 billion. Third-quarter 2016 net
earnings included after-tax intangible amortization expense of
approximately $0.2 billion and a
charge for after-tax special items of approximately $0.2 billion. Excluding after-tax intangible
amortization expense and special items, adjusted net earnings for
the current quarter were $5.2 billion
and adjusted diluted earnings per share were $1.90, representing increases of 11.2% and 13.1%,
respectively, as compared to the same period in 2016.*
On an operational basis, adjusted diluted earnings per share also
increased 10.1%.* A reconciliation of non-GAAP financial
measures is included as an accompanying schedule.
"Johnson & Johnson accelerated growth in the third
quarter. This is driven by the strong performance of our
Pharmaceutical business, and augmented by Actelion and other recent
acquisitions across the enterprise that will continue to fuel
growth," said Alex Gorsky, Chairman
and Chief Executive Officer. "Our dedicated colleagues continue to
focus on advancing our pipelines to bring innovative solutions to
patients and consumers around the globe."
The Company increased its sales guidance for the full-year 2017
to a range of $76.1 billion to $76.5
billion. Additionally, the Company increased its adjusted
earnings guidance for full-year 2017 to $7.25 - $7.30 per share.*
Worldwide Consumer sales of $3.4
billion for the third quarter 2017 represented an increase
of 2.9% versus the prior year, consisting of an operational
increase of 1.6% and a positive impact from currency of 1.3%.
Domestic sales decreased 0.5%, international sales increased 5.1%,
which reflected an operational increase of 3.0% and a positive
currency impact of 2.1%. Excluding the net impact of acquisitions
and divestitures, on an operational basis, worldwide sales
increased 1.1%, domestic sales decreased 0.7% and international
sales increased 2.3%*.
Worldwide operational results, excluding the net impact of
acquisitions and divestitures, were driven by over-the-counter
products primarily TYLENOL® analgesic
products and international smoking cessation aids; as
well as OGX® and NEUTROGENA® beauty products
partially offset by the negative impact of domestic baby care
products.
During the quarter, the divestiture of COMPEED® to
HRA Pharma was completed.
Worldwide Pharmaceutical sales of $9.7
billion for the third quarter 2017 represented an increase
of 15.4% versus the prior year with an operational increase of
14.6% and a positive impact from currency of 0.8%. Domestic sales
increased 15.4%; international sales increased 15.5%, which
reflected an operational increase of 13.5% and a positive currency
impact of 2.0%. Sales included the impact of the first full quarter
of the acquisition of Actelion Ltd. which contributed 7.9%, to
worldwide operational sales growth. Excluding the net impact of
acquisitions and divestitures, on an operational basis, worldwide
sales increased 6.7%, domestic sales increased 7.7% and
international sales increased 5.1%.*
Worldwide operational results, excluding the net impact of
acquisitions and divestitures, were driven by new products and the
strength of core products. Strong growth in new products include
DARZALEX® (daratumumab), for the treatment of patients
with multiple myeloma and IMBRUVICA® (ibrutinib), an
oral, once-daily therapy approved for use in treating certain
B-cell malignancies, a type of blood or lymph node cancer.
Additional contributors to operational sales growth included
STELARA® (ustekinumab), a biologic for the treatment of
a number of immune-mediated inflammatory diseases,
XARELTO® (rivaroxaban), an oral anticoagulant,
ZYTIGA® (abiraterone acetate), an oral, once-daily
medication for use in combination with prednisone for the treatment
of metastatic, castration-resistant prostate cancer and
INVEGA®
SUSTENNA®/XEPLION®/TRINZA®
(paliperidone palmitate), long-acting, injectable atypical
antipsychotics for the treatment of schizophrenia in adults.
During the quarter, the U.S. Food and Drug Administration (FDA)
approved an additional indication for IMBRUVICA®
(ibrutinib) for the treatment of adult patients with chronic
graft-versus-host-disease after failure of one or more lines of
systemic therapy. The European Commission granted approval
for SYMTUZA® (darunavir/cobicistat/
emtricitabine/tenofovir alafenamide) for the treatment of human
immunodeficiency virus type 1 (HIV-1) infection in adults and
pediatric patients aged 12 years and older.
New Drug Applications were submitted to the FDA for apalutamide,
an oral androgen receptor inhibitor for men with non-metastatic
castration-resistant prostate cancer and also for
darunavir/cobicistat/emtricitabine/tenofovir alafenamide for the
treatment of HIV-1 infection in adults and pediatric patients aged
12 years and older. In addition, a supplemental New
Drug Application (sNDA) was submitted to the FDA to expand the
indication for ZYTIGA® (abiraterone acetate), in
combination with prednisone and ADT to include treatment of
patients with high-risk metastatic hormone naïve prostate cancer or
newly diagnosed, high-risk metastatic hormone sensitive prostate
cancer.
The Company has made a decision not to pursue global approvals
of sirukumab for the treatment of moderately to severely active
rheumatoid arthritis. In addition, the clinical trial for
talacotuzumab, an investigational compound being studied in
patients with acute myeloid leukemia, has been discontinued.
Worldwide Medical Devices sales of $6.6
billion for the third quarter 2017 represented an increase
of 7.1% versus the prior year consisting of an operational increase
of 6.6% and a positive currency impact of 0.5%. Domestic sales
increased 4.6%; international sales increased 9.6%, which reflected
an operational increase of 8.6% and a positive currency impact of
1.0%. Sales included the impact of the acquisition of Abbott
Medical Optics which contributed 5.2%, to worldwide operational
sales growth. Excluding the net impact of acquisitions and
divestitures, on an operational basis, worldwide sales increased
1.2%, domestic sales decreased 0.8% and international sales
increased 3.2%.*
Worldwide operational results, excluding the net impact of
acquisitions and divestitures, were driven by electrophysiology
products in the Cardiovascular business, ACUVUE® contact
lenses in the Vision Care business, and wound closure products in
the General Surgery business, partially offset by declines in the
Diabetes Care business.
During the quarter, the acquisitions of TearScience, Inc., a
manufacturer of products dedicated to treating meibomian gland
dysfunction and Sightbox, Inc., an e-commerce company that provides
subscription vision care services connecting consumers with eye
care professionals for their contact lens needs, were
completed.
Subsequent to the quarter, the Company announced the completion
of the divestiture of its Codman Neurosurgery business
to Integra LifeSciences Holding Corporation.
About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites
the people of Johnson & Johnson. We embrace research and
science - bringing innovative ideas, products and services to
advance the health and well-being of people. Our approximately
134,100 employees at more than 250 Johnson & Johnson operating
companies work with partners in health care to touch the lives of
over a billion people every day, throughout the world.
* Operational sales growth excluding the net impact
of acquisitions and divestitures, as well as adjusted net earnings,
adjusted diluted earnings per share and operational adjusted
diluted earnings per share excluding after-tax intangible
amortization expense and special items, are non-GAAP financial
measures and should not be considered replacements for, and should
be read together with, the most comparable GAAP financial measures.
Except for guidance measures, reconciliations of these non-GAAP
financial measures to the most directly comparable GAAP financial
measures can be found in the accompanying financial schedules of
the earnings release and the Investor Relations section of the
company's website at www.investor.jnj.com. Johnson & Johnson
does not provide GAAP financial measures on a forward-looking basis
because the company is unable to predict with reasonable certainty
the ultimate outcome of legal proceedings, unusual gains and
losses, acquisition-related expenses and purchase accounting fair
value adjustments without unreasonable effort. These items are
uncertain, depend on various factors, and could be material to
Johnson & Johnson's results computed in accordance with
GAAP.
Johnson & Johnson will conduct a conference call with
investors to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast
of the call for investors and other interested parties may be
accessed by visiting the Johnson & Johnson website at
www.investor.jnj.com. A replay and podcast will be available
approximately two hours after the live webcast by visiting
www.investor.jnj.com.
Copies of the financial schedules accompanying this press
release are available at www.investor.jnj.com/historical-sales.cfm.
These schedules include supplementary sales data, a condensed
consolidated statement of earnings, reconciliations of non-GAAP
financial measures, and sales of key products/franchises.
Additional information on Johnson & Johnson, including adjusted
income before tax by segment, a pharmaceutical pipeline of selected
compounds in late stage development and a copy of today's earnings
call presentation can be found on the company's website at
www.investor.jnj.com.
NOTE TO INVESTORS CONCERNING FORWARD-LOOKING
STATEMENTS
This press release contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things, future operating and financial
performance, product development, market position and business
strategy. The reader is cautioned not to rely on these
forward-looking statements. These statements are based on current
expectations of future events. If underlying assumptions prove
inaccurate or known or unknown risks or uncertainties materialize,
actual results could vary materially from the expectations and
projections of Johnson & Johnson. Risks and uncertainties
include, but are not limited to: economic and financial market
factors, such as interest rate and currency exchange rate
fluctuations; competition, including technological advances, new
products and patents attained by competitors; challenges inherent
in product research and development, including uncertainty of
clinical success and obtaining regulatory approvals; uncertainty of
commercial success for new and existing products; challenges to
patents; the impact of patent expirations; the ability of the
company to successfully execute strategic plans, including
restructuring plans; the impact of business combinations and
divestitures, including the Company's ability to successfully
integrate Actelion Ltd.'s products and operations and realize the
expected benefits and opportunities of the transaction in the
expected time frame or at all; significant adverse litigation or
government action, including related to product liability claims;
changes to applicable laws and regulations, including tax laws and
global health care reforms; trends toward health care cost
containment; changes in behavior and spending patterns of
purchasers of health care products and services; financial
instability of international economies and legal systems and
sovereign risk; manufacturing difficulties or delays, internally or
within the supply chain; product efficacy or safety concerns
resulting in product recalls or regulatory action; increased
scrutiny of the health care industry by government agencies; and
the potential failure to meet obligations in compliance agreements
with government bodies. A further list and descriptions of these
risks, uncertainties and other factors can be found in Johnson
& Johnson's Annual Report on Form 10-K for the fiscal year
ended January 1, 2017, including
under "Item 1A. Risk Factors," its most recently filed Quarterly
Report on Form 10-Q, including in the section captioned "Cautionary
Note Regarding Forward-Looking Statements," and the company's
subsequent filings with the Securities and Exchange Commission.
Copies of these filings are available online at www.sec.gov,
www.investor.jnj.com, or on request from Johnson & Johnson. Any
forward-looking statement made in this release speaks only as of
the date of this release. Johnson & Johnson does not undertake
to update any forward-looking statement as a result of new
information or future events or developments.
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplementary
Sales Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars
in Millions)
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
Percent
Change
|
|
|
|
|
|
Percent
Change
|
|
2017
|
|
2016
|
|
Total
|
|
Operations
|
|
Currency
|
|
2017
|
|
2016
|
|
Total
|
|
Operations
|
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
segment of
business
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
1,285
|
|
$
1,291
|
|
(0.5)
|
%
|
(0.5)
|
|
-
|
|
$
4,186
|
|
$
4,033
|
|
3.8
|
%
|
3.8
|
|
-
|
International
|
2,071
|
|
1,970
|
|
5.1
|
|
3.0
|
|
2.1
|
|
5,876
|
|
5,842
|
|
0.6
|
|
0.2
|
|
0.4
|
|
3,356
|
|
3,261
|
|
2.9
|
|
1.6
|
|
1.3
|
|
10,062
|
|
9,875
|
|
1.9
|
|
1.6
|
|
0.3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
5,816
|
|
5,042
|
|
15.4
|
|
15.4
|
|
-
|
|
15,698
|
|
15,123
|
|
3.8
|
|
3.8
|
|
-
|
International
|
3,879
|
|
3,358
|
|
15.5
|
|
13.5
|
|
2.0
|
|
10,877
|
|
10,109
|
|
7.6
|
|
8.4
|
|
(0.8)
|
|
9,695
|
|
8,400
|
|
15.4
|
|
14.6
|
|
0.8
|
|
26,575
|
|
25,232
|
|
5.3
|
|
5.6
|
|
(0.3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Medical
Devices
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
3,189
|
|
3,048
|
|
4.6
|
|
4.6
|
|
-
|
|
9,510
|
|
9,118
|
|
4.3
|
|
4.3
|
|
-
|
International
|
3,410
|
|
3,111
|
|
9.6
|
|
8.6
|
|
1.0
|
|
10,108
|
|
9,559
|
|
5.7
|
|
6.3
|
|
(0.6)
|
|
6,599
|
|
6,159
|
|
7.1
|
|
6.6
|
|
0.5
|
|
19,618
|
|
18,677
|
|
5.0
|
|
5.3
|
|
(0.3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
10,290
|
|
9,381
|
|
9.7
|
|
9.7
|
|
-
|
|
29,394
|
|
28,274
|
|
4.0
|
|
4.0
|
|
-
|
International
|
9,360
|
|
8,439
|
|
10.9
|
|
9.3
|
|
1.6
|
|
26,861
|
|
25,510
|
|
5.3
|
|
5.8
|
|
(0.5)
|
Worldwide
|
$
19,650
|
|
$
17,820
|
|
10.3
|
%
|
9.5
|
|
0.8
|
|
$
56,255
|
|
$
53,784
|
|
4.6
|
%
|
4.8
|
|
(0.2)
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplementary
Sales Data
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; Dollars
in Millions)
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
Percent
Change
|
|
|
|
|
|
Percent
Change
|
|
2017
|
|
2016
|
|
Total
|
|
Operations
|
|
Currency
|
|
2017
|
|
2016
|
|
Total
|
|
Operations
|
|
Currency
|
Sales to customers
by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
geographic
area
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S.
|
$
10,290
|
|
$
9,381
|
|
9.7
|
%
|
9.7
|
|
-
|
|
$
29,394
|
|
$
28,274
|
|
4.0
|
%
|
4.0
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Europe
|
4,308
|
|
3,832
|
|
12.4
|
|
7.9
|
|
4.5
|
|
12,398
|
|
11,769
|
|
5.3
|
|
6.2
|
|
(0.9)
|
Western Hemisphere
excluding U.S.
|
1,569
|
|
1,396
|
|
12.4
|
|
10.1
|
|
2.3
|
|
4,522
|
|
4,269
|
|
5.9
|
|
3.1
|
|
2.8
|
Asia-Pacific,
Africa
|
3,483
|
|
3,211
|
|
8.5
|
|
10.6
|
|
(2.1)
|
|
9,941
|
|
9,472
|
|
5.0
|
|
6.4
|
|
(1.4)
|
International
|
9,360
|
|
8,439
|
|
10.9
|
|
9.3
|
|
1.6
|
|
26,861
|
|
25,510
|
|
5.3
|
|
5.8
|
|
(0.5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Worldwide
|
$
19,650
|
|
$
17,820
|
|
10.3
|
%
|
9.5
|
|
0.8
|
|
$
56,255
|
|
$
53,784
|
|
4.6
|
%
|
4.8
|
|
(0.2)
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
Condensed
Consolidated Statement of Earnings
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in
Millions Except Per Share Figures)
|
THIRD
QUARTER
|
|
|
|
|
|
|
|
|
|
|
|
2017
|
|
2016
|
|
Percent
|
|
|
|
Percent
|
|
|
|
Percent
|
|
Increase
|
|
Amount
|
|
to
Sales
|
|
Amount
|
|
to
Sales
|
|
(Decrease)
|
Sales to
customers
|
$
19,650
|
|
100.0
|
|
$
17,820
|
|
100.0
|
|
10.3
|
Cost of products
sold
|
6,902
|
|
35.1
|
|
5,486
|
|
30.8
|
|
25.8
|
Selling, marketing
and administrative expenses
|
5,396
|
|
27.5
|
|
4,772
|
|
26.8
|
|
13.1
|
Research and
development expense
|
2,574
|
|
13.1
|
|
2,178
|
|
12.2
|
|
18.2
|
Interest (income)
expense, net
|
155
|
|
0.8
|
|
95
|
|
0.5
|
|
|
Other (income)
expense, net
|
(236)
|
|
(1.2)
|
|
(54)
|
|
(0.2)
|
|
|
Restructuring
|
69
|
|
0.3
|
|
62
|
|
0.3
|
|
|
Earnings before
provision for taxes on income
|
4,790
|
|
24.4
|
|
5,281
|
|
29.6
|
|
(9.3)
|
Provision for
taxes on income
|
1,026
|
|
5.2
|
|
1,009
|
|
5.6
|
|
1.7
|
Net
earnings
|
$
3,764
|
|
19.2
|
|
$
4,272
|
|
24.0
|
|
(11.9)
|
|
|
|
|
|
|
|
|
|
|
Net earnings per
share (Diluted)
|
$
1.37
|
|
|
|
$
1.53
|
|
|
|
(10.5)
|
|
|
|
|
|
|
|
|
|
|
Average shares
outstanding (Diluted)
|
2,737.7
|
|
|
|
2,785.4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
21.4
|
%
|
|
|
19.1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings
before provision for taxes and net earnings
(1)
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income
|
$
6,573
|
|
33.5
|
|
$
5,831
|
|
32.7
|
|
12.7
|
Net
earnings
|
$
5,208
|
|
26.5
|
|
$
4,683
|
|
26.3
|
|
11.2
|
Net earnings per
share (Diluted)
|
$
1.90
|
|
|
|
$
1.68
|
|
|
|
13.1
|
Effective tax
rate
|
20.8
|
%
|
|
|
19.7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) See
Reconciliation of Non-GAAP Financial Measures.
|
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
Condensed
Consolidated Statement of Earnings
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Unaudited; in
Millions Except Per Share Figures)
|
NINE
MONTHS
|
|
|
|
|
|
|
|
|
|
|
|
2017
|
|
2016
|
|
Percent
|
|
|
|
Percent
|
|
|
|
Percent
|
|
Increase
|
|
Amount
|
|
to
Sales
|
|
Amount
|
|
to
Sales
|
|
(Decrease)
|
Sales to
customers
|
$
56,255
|
|
100.0
|
|
$
53,784
|
|
100.0
|
|
4.6
|
Cost of products
sold
|
18,111
|
|
32.2
|
|
16,151
|
|
30.0
|
|
12.1
|
Selling, marketing
and administrative expenses
|
15,395
|
|
27.4
|
|
14,636
|
|
27.2
|
|
5.2
|
Research and
development expense
|
6,919
|
|
12.3
|
|
6,455
|
|
12.0
|
|
7.2
|
In-process
research and development
|
-
|
|
-
|
|
29
|
|
0.1
|
|
|
Interest (income)
expense, net
|
360
|
|
0.6
|
|
274
|
|
0.5
|
|
|
Other (income)
expense, net
|
192
|
|
0.3
|
|
464
|
|
0.9
|
|
|
Restructuring
|
165
|
|
0.3
|
|
296
|
|
0.5
|
|
|
Earnings before
provision for taxes on income
|
15,113
|
|
26.9
|
|
15,479
|
|
28.8
|
|
(2.4)
|
Provision for
taxes on income
|
3,100
|
|
5.5
|
|
2,753
|
|
5.1
|
|
12.6
|
Net
earnings
|
$
12,013
|
|
21.4
|
|
$
12,726
|
|
23.7
|
|
(5.6)
|
|
|
|
|
|
|
|
|
|
|
Net earnings per
share (Diluted)
|
$
4.37
|
|
|
|
$
4.55
|
|
|
|
(4.0)
|
|
|
|
|
|
|
|
|
|
|
Average shares
outstanding (Diluted)
|
2,746.4
|
|
|
|
2,796.6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective tax
rate
|
20.5
|
%
|
|
|
17.8
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings
before provision for taxes and net earnings
(1)
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income
|
$
18,961
|
|
33.7
|
|
$
17,656
|
|
32.8
|
|
7.4
|
Net
earnings
|
$
15,263
|
|
27.1
|
|
$
14,403
|
|
26.8
|
|
6.0
|
Net earnings per
share (Diluted)
|
$
5.56
|
|
|
|
$
5.15
|
|
|
|
8.0
|
Effective tax
rate
|
19.5
|
%
|
|
|
18.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) See
Reconciliation of Non-GAAP Financial Measures.
|
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measures
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Third
Quarter
|
|
% Incr. /
|
|
|
Nine Months
YTD
|
|
% Incr. /
|
|
(Dollars in
Millions Except Per Share Data)
|
|
2017
|
|
2016
|
|
(Decr.)
|
|
|
2017
|
|
2016
|
|
(Decr.)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income - as reported
|
|
$ 4,790
|
|
5,281
|
|
(9.3)
|
%
|
|
$ 15,113
|
|
15,479
|
|
(2.4)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible asset
amortization expense
|
|
1,077
|
|
319
|
|
|
|
|
1,886
|
|
927
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Litigation expense,
net
|
|
118
|
|
55
|
|
|
|
|
611
|
|
721
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring/Other
(1)
|
|
187
|
|
109
|
|
|
|
|
476
|
|
387
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Actelion acquisition
related cost
|
|
367
|
|
-
|
|
|
|
|
580
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diabetes asset
impairment
|
|
(2)
|
|
-
|
|
|
|
|
180
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AMO acquisition
related cost
|
|
36
|
|
-
|
|
|
|
|
115
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In-process research
and development
|
|
-
|
|
-
|
|
|
|
|
-
|
|
29
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
-
|
|
67
|
|
|
|
|
-
|
|
113
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before
provision for taxes on income - as adjusted
|
|
$ 6,573
|
|
5,831
|
|
12.7
|
%
|
|
$ 18,961
|
|
17,656
|
|
7.4
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Earnings - as
reported
|
|
$ 3,764
|
|
4,272
|
|
(11.9)
|
%
|
|
$ 12,013
|
|
12,726
|
|
(5.6)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible asset
amortization expense
|
|
933
|
|
236
|
|
|
|
|
1,555
|
|
679
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Litigation expense,
net
|
|
97
|
|
46
|
|
|
|
|
449
|
|
595
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring/Other
|
|
136
|
|
76
|
|
|
|
|
358
|
|
293
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Actelion acquisition
related cost
|
|
255
|
|
-
|
|
|
|
|
454
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diabetes asset
impairment
|
|
(5)
|
|
-
|
|
|
|
|
120
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AMO acquisition
related cost
|
|
28
|
|
-
|
|
|
|
|
314
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In-process research
and development
|
|
-
|
|
-
|
|
|
|
|
-
|
|
23
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
-
|
|
53
|
|
|
|
|
-
|
|
87
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Earnings - as
adjusted
|
|
$ 5,208
|
|
4,683
|
|
11.2
|
%
|
|
$ 15,263
|
|
14,403
|
|
6.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted Net Earnings
per share - as reported
|
|
$
1.37
|
|
1.53
|
|
(10.5)
|
%
|
|
$
4.37
|
|
4.55
|
|
(4.0)
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible asset
amortization expense
|
|
0.34
|
|
0.08
|
|
|
|
|
0.57
|
|
0.24
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Litigation expense,
net
|
|
0.04
|
|
0.02
|
|
|
|
|
0.16
|
|
0.21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Restructuring/Other
|
|
0.05
|
|
0.03
|
|
|
|
|
0.14
|
|
0.11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Actelion acquisition
related cost
|
|
0.09
|
|
-
|
|
|
|
|
0.16
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diabetes asset
impairment
|
|
-
|
|
-
|
|
|
|
|
0.05
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AMO acquisition
related cost
|
|
0.01
|
|
-
|
|
|
|
|
0.11
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In-process research
and development
|
|
-
|
|
-
|
|
|
|
|
-
|
|
0.01
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other
|
|
-
|
|
0.02
|
|
|
|
|
-
|
|
0.03
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted Net Earnings
per share - as adjusted
|
|
$
1.90
|
|
1.68
|
|
13.1
|
%
|
|
$
5.56
|
|
5.15
|
|
8.0
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Diluted
Net Earnings per share - as adjusted at
2015 foreign currency exchange rates
|
|
|
|
1.68
|
|
|
|
|
|
|
5.19
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact of currency at
2016 foreign currency exchange rates
|
|
(0.05)
|
|
-
|
|
|
|
|
0.01
|
|
(0.04)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Diluted
Net Earnings per share - as adjusted at
2016 foreign currency exchange rates
|
|
$
1.85
|
|
1.68
|
|
10.1
|
%
|
|
$
5.57
|
|
5.15
|
|
8.2
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) Includes $29M
recorded in cost of products sold and $89M recorded in other
(income) expense for the third quarter 2017. Includes $46M recorded
in cost of products sold
|
|
and $265M recorded in
other (income) expense for nine months 2017 YTD. Includes $3M
recorded in cost of products sold and $44M recorded in other
(income) expense for the
|
|
third quarter
2016. Includes $27M recorded in cost of products sold and
$64M recorded in other (income) expense for nine months 2016
YTD.
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measure
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Sales
Growth Excluding Acquisitions and Divestitures
|
THIRD
QUARTER 2017 ACTUAL vs. 2016 ACTUAL
|
|
|
|
|
|
|
|
|
|
|
Segments
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
|
|
Pharmaceutical
|
|
Medical
Devices
|
|
Total
|
|
|
Operational
%(1)
|
WW As
Reported:
|
|
1.6%
|
|
14.6%
|
|
6.6%
|
|
9.5%
|
U.S.
|
|
(0.5)%
|
|
15.4%
|
|
4.6%
|
|
9.7%
|
International
|
|
3.0%
|
|
13.5%
|
|
8.6%
|
|
9.3%
|
|
|
|
|
|
|
|
|
|
Beauty
|
|
|
|
|
|
|
|
|
Dr. Ci:
Labo
|
|
(0.6)
|
|
|
|
|
|
(0.1)
|
U.S.
|
|
0.0
|
|
|
|
|
|
0.0
|
International
|
|
(1.0)
|
|
|
|
|
|
(0.2)
|
|
|
|
|
|
|
|
|
|
Vision
Care
|
|
|
|
|
|
|
|
|
Abbott Medical
Optics
|
|
|
|
|
|
(5.2)
|
|
(1.8)
|
U.S.
|
|
|
|
|
|
(4.6)
|
|
(1.5)
|
International
|
|
|
|
|
|
(5.7)
|
|
(2.1)
|
|
|
|
|
|
|
|
|
|
Pulmonary
Hypertension
|
|
|
|
|
|
|
|
|
Actelion
|
|
|
|
(7.9)
|
|
|
|
(3.7)
|
U.S.
|
|
|
|
(7.7)
|
|
|
|
(4.1)
|
International
|
|
|
|
(8.4)
|
|
|
|
(3.3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All Other
Acquisitions and Divestitures
|
|
0.1
|
|
|
|
(0.2)
|
|
(0.1)
|
U.S.
|
|
(0.2)
|
|
|
|
(0.8)
|
|
(0.3)
|
International
|
|
0.3
|
|
|
|
0.3
|
|
0.1
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Acquisitions and Divestitures
|
|
1.1%
|
|
6.7%
|
|
1.2%
|
|
3.8%
|
U.S.
|
|
(0.7)%
|
|
7.7%
|
|
(0.8)%
|
|
3.8%
|
International
|
|
2.3%
|
|
5.1%
|
|
3.2%
|
|
3.8%
|
|
|
|
|
|
|
|
|
|
(1)
Operational growth excludes the effect of translational
currency
|
|
|
|
|
|
|
|
|
Johnson &
Johnson and Subsidiaries
|
|
|
|
|
|
|
|
|
Reconciliation of
Non-GAAP Financial Measure
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operational Sales
Growth Excluding Acquisitions and Divestitures
|
NINE MONTHS
2017 ACTUAL vs. 2016 ACTUAL
|
|
Segments
|
|
|
|
|
|
|
|
|
|
|
|
Consumer
|
|
Pharmaceutical
|
|
Medical
Devices
|
|
Total
|
|
|
Operational
%(1)
|
WW As
Reported:
|
|
1.6%
|
|
5.6%
|
|
5.3%
|
|
4.8%
|
U.S.
|
|
3.8%
|
|
3.8%
|
|
4.3%
|
|
4.0%
|
International
|
|
0.2%
|
|
8.4%
|
|
6.3%
|
|
5.8%
|
|
|
|
|
|
|
|
|
|
Beauty
|
|
|
|
|
|
|
|
|
Vogue
|
|
(1.9)
|
|
|
|
|
|
(0.4)
|
U.S.
|
|
(4.1)
|
|
|
|
|
|
(0.6)
|
International
|
|
(0.5)
|
|
|
|
|
|
(0.1)
|
|
|
|
|
|
|
|
|
|
Other
Neuroscience
|
|
|
|
|
|
|
|
|
Controlled
Substance Raw Material and API Business
|
|
|
|
0.5
|
|
|
|
0.2
|
U.S.
|
|
|
|
0.6
|
|
|
|
0.3
|
International
|
|
|
|
0.3
|
|
|
|
0.1
|
|
|
|
|
|
|
|
|
|
Diagnostics
|
|
|
|
|
|
|
|
|
Ortho-Clinical
Diagnostics
|
|
|
|
|
|
0.4
|
|
0.1
|
U.S.
|
|
|
|
|
|
0.0
|
|
0.0
|
International
|
|
|
|
|
|
0.8
|
|
0.3
|
|
|
|
|
|
|
|
|
|
Beauty
|
|
|
|
|
|
|
|
|
Dr. Ci:
Labo
|
|
(0.3)
|
|
|
|
|
|
(0.1)
|
U.S.
|
|
0.0
|
|
|
|
|
|
0.0
|
International
|
|
(0.5)
|
|
|
|
|
|
(0.1)
|
|
|
|
|
|
|
|
|
|
Vision
Care
|
|
|
|
|
|
|
|
|
Abbott Medical
Optics
|
|
|
|
|
|
(4.1)
|
|
(1.4)
|
U.S.
|
|
|
|
|
|
(3.7)
|
|
(1.2)
|
International
|
|
|
|
|
|
(4.6)
|
|
(1.7)
|
|
|
|
|
|
|
|
|
|
Pulmonary
Hypertension
|
|
|
|
|
|
|
|
|
Actelion
|
|
|
|
(3.0)
|
|
|
|
(1.4)
|
U.S.
|
|
|
|
(2.8)
|
|
|
|
(1.5)
|
International
|
|
|
|
(3.3)
|
|
|
|
(1.3)
|
|
|
|
|
|
|
|
|
|
All Other
Acquisitions and Divestitures
|
|
(0.1)
|
|
|
|
(0.3)
|
|
0.0
|
U.S.
|
|
(0.4)
|
|
|
|
(0.7)
|
|
(0.3)
|
International
|
|
0.2
|
|
|
|
0.2
|
|
0.0
|
|
|
|
|
|
|
|
|
|
WW Ops excluding
Acquisitions and Divestitures
|
|
(0.7)%
|
|
3.1%
|
|
1.3%
|
|
1.8%
|
U.S.
|
|
(0.7)%
|
|
1.6%
|
|
(0.1)%
|
|
0.7%
|
International
|
|
(0.6)%
|
|
5.4%
|
|
2.7%
|
|
3.0%
|
|
|
|
|
|
|
|
|
|
(1) Operational
growth excludes the effect of translational
currency
|
|
|
|
|
|
|
|
|
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2017
|
|
2016
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2017
|
|
2016
|
Reported
|
Operational
(1)
|
Currency
|
CONSUMER SEGMENT
(2) (3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BABY CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
100
|
|
$
118
|
-15.3%
|
-15.3%
|
-
|
|
|
$
326
|
|
$
365
|
-10.7%
|
-10.7%
|
-
|
Intl
|
|
377
|
|
377
|
0.0%
|
0.0%
|
0.0%
|
|
|
1,100
|
|
1,143
|
-3.8%
|
-3.8%
|
0.0%
|
WW
|
|
477
|
|
495
|
-3.6%
|
-3.6%
|
0.0%
|
|
|
1,426
|
|
1,508
|
-5.4%
|
-5.4%
|
0.0%
|
BEAUTY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
523
|
|
517
|
1.2%
|
1.2%
|
-
|
|
|
1,739
|
|
1,555
|
11.8%
|
11.8%
|
-
|
Intl
|
|
510
|
|
462
|
10.4%
|
8.0%
|
2.4%
|
|
|
1,351
|
|
1,279
|
5.6%
|
5.4%
|
0.2%
|
WW
|
|
1,033
|
|
979
|
5.5%
|
4.4%
|
1.1%
|
|
|
3,090
|
|
2,834
|
9.0%
|
8.9%
|
0.1%
|
ORAL CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
154
|
|
156
|
-1.3%
|
-1.3%
|
-
|
|
|
460
|
|
485
|
-5.2%
|
-5.2%
|
-
|
Intl
|
|
228
|
|
227
|
0.4%
|
-1.4%
|
1.8%
|
|
|
678
|
|
686
|
-1.2%
|
-1.6%
|
0.4%
|
WW
|
|
382
|
|
383
|
-0.3%
|
-1.3%
|
1.0%
|
|
|
1,138
|
|
1,171
|
-2.8%
|
-3.0%
|
0.2%
|
OTC
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
401
|
|
386
|
3.9%
|
3.9%
|
-
|
|
|
1,310
|
|
1,257
|
4.2%
|
4.2%
|
-
|
Intl
|
|
601
|
|
557
|
7.9%
|
4.7%
|
3.2%
|
|
|
1,711
|
|
1,681
|
1.8%
|
1.4%
|
0.4%
|
WW
|
|
1,002
|
|
943
|
6.3%
|
4.4%
|
1.9%
|
|
|
3,021
|
|
2,938
|
2.8%
|
2.6%
|
0.2%
|
WOMEN'S
HEALTH
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
3
|
|
3
|
0.0%
|
0.0%
|
-
|
|
|
9
|
|
16
|
-43.8%
|
-43.8%
|
-
|
Intl
|
|
267
|
|
266
|
0.4%
|
-1.9%
|
2.3%
|
|
|
779
|
|
787
|
-1.0%
|
-2.6%
|
1.6%
|
WW
|
|
270
|
|
269
|
0.4%
|
-1.8%
|
2.2%
|
|
|
788
|
|
803
|
-1.9%
|
-3.5%
|
1.6%
|
WOUND CARE /
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
104
|
|
111
|
-6.3%
|
-6.3%
|
-
|
|
|
342
|
|
355
|
-3.7%
|
-3.7%
|
-
|
Intl
|
|
88
|
|
81
|
8.6%
|
5.9%
|
2.7%
|
|
|
257
|
|
266
|
-3.4%
|
-4.0%
|
0.6%
|
WW
|
|
192
|
|
192
|
0.0%
|
-1.2%
|
1.2%
|
|
|
599
|
|
621
|
-3.5%
|
-3.8%
|
0.3%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL
CONSUMER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,285
|
|
1,291
|
-0.5%
|
-0.5%
|
-
|
|
|
4,186
|
|
4,033
|
3.8%
|
3.8%
|
-
|
Intl
|
|
2,071
|
|
1,970
|
5.1%
|
3.0%
|
2.1%
|
|
|
5,876
|
|
5,842
|
0.6%
|
0.2%
|
0.4%
|
WW
|
|
$
3,356
|
|
$
3,261
|
2.9%
|
1.6%
|
1.3%
|
|
|
$
10,062
|
|
$
9,875
|
1.9%
|
1.6%
|
0.3%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2017
|
|
2016
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2017
|
|
2016
|
Reported
|
Operational
(1)
|
Currency
|
PHARMACEUTICAL
SEGMENT (2) (3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IMMUNOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
2,420
|
|
$
2,294
|
5.5%
|
5.5%
|
-
|
|
|
$
6,644
|
|
$
6,689
|
-0.7%
|
-0.7%
|
-
|
Intl
|
|
849
|
|
790
|
7.5%
|
4.9%
|
2.6%
|
|
|
2,514
|
|
2,343
|
7.3%
|
7.3%
|
0.0%
|
WW
|
|
3,269
|
|
3,084
|
6.0%
|
5.3%
|
0.7%
|
|
|
9,158
|
|
9,032
|
1.4%
|
1.4%
|
0.0%
|
REMICADE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,206
|
|
1,222
|
-1.3%
|
-1.3%
|
-
|
|
|
3,452
|
|
3,669
|
-5.9%
|
-5.9%
|
-
|
US Exports
(4)
|
|
156
|
|
255
|
-38.8%
|
-38.8%
|
-
|
|
|
448
|
|
673
|
-33.4%
|
-33.4%
|
-
|
Intl
|
|
285
|
|
306
|
-6.9%
|
-10.2%
|
3.3%
|
|
|
949
|
|
1,000
|
-5.1%
|
-5.9%
|
0.8%
|
WW
|
|
1,647
|
|
1,783
|
-7.6%
|
-8.2%
|
0.6%
|
|
|
4,849
|
|
5,342
|
-9.2%
|
-9.4%
|
0.2%
|
SIMPONI /
SIMPONI ARIA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
242
|
|
256
|
-5.5%
|
-5.5%
|
-
|
|
|
701
|
|
716
|
-2.1%
|
-2.1%
|
-
|
Intl
|
|
234
|
|
225
|
4.0%
|
3.2%
|
0.8%
|
|
|
642
|
|
603
|
6.5%
|
6.6%
|
-0.1%
|
WW
|
|
476
|
|
481
|
-1.0%
|
-1.4%
|
0.4%
|
|
|
1,343
|
|
1,319
|
1.8%
|
1.9%
|
-0.1%
|
STELARA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
800
|
|
561
|
42.6%
|
42.6%
|
-
|
|
|
2,027
|
|
1,631
|
24.3%
|
24.3%
|
-
|
Intl
|
|
324
|
|
253
|
28.1%
|
24.7%
|
3.4%
|
|
|
903
|
|
722
|
25.1%
|
26.1%
|
-1.0%
|
WW
|
|
1,124
|
|
814
|
38.1%
|
37.0%
|
1.1%
|
|
|
2,930
|
|
2,353
|
24.5%
|
24.8%
|
-0.3%
|
OTHER
IMMUNOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
16
|
|
-
|
*
|
*
|
-
|
|
|
16
|
|
-
|
*
|
*
|
-
|
Intl
|
|
6
|
|
6
|
-
|
-
|
-
|
|
|
20
|
|
18
|
11.1%
|
9.4%
|
1.7%
|
WW
|
|
22
|
|
6
|
*
|
*
|
-
|
|
|
36
|
|
18
|
100.0%
|
98.3%
|
1.7%
|
INFECTIOUS
DISEASES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
353
|
|
387
|
-8.8%
|
-8.8%
|
-
|
|
|
1,020
|
|
1,107
|
-7.9%
|
-7.9%
|
-
|
Intl
|
|
460
|
|
455
|
1.1%
|
-2.3%
|
3.4%
|
|
|
1,334
|
|
1,340
|
-0.4%
|
-0.4%
|
0.0%
|
WW
|
|
813
|
|
842
|
-3.4%
|
-5.3%
|
1.9%
|
|
|
2,354
|
|
2,447
|
-3.8%
|
-3.8%
|
0.0%
|
EDURANT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
15
|
|
13
|
15.4%
|
15.4%
|
-
|
|
|
44
|
|
38
|
15.8%
|
15.8%
|
-
|
Intl
|
|
179
|
|
136
|
31.6%
|
26.0%
|
5.6%
|
|
|
478
|
|
370
|
29.2%
|
28.9%
|
0.3%
|
WW
|
|
194
|
|
149
|
30.2%
|
25.1%
|
5.1%
|
|
|
522
|
|
408
|
27.9%
|
27.7%
|
0.2%
|
PREZISTA /
PREZCOBIX / REZOLSTA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
287
|
|
310
|
-7.4%
|
-7.4%
|
-
|
|
|
824
|
|
860
|
-4.2%
|
-4.2%
|
-
|
Intl
|
|
180
|
|
183
|
-1.6%
|
-5.5%
|
3.9%
|
|
|
527
|
|
544
|
-3.1%
|
-2.7%
|
-0.4%
|
WW
|
|
467
|
|
493
|
-5.3%
|
-6.7%
|
1.4%
|
|
|
1,351
|
|
1,404
|
-3.8%
|
-3.7%
|
-0.1%
|
OTHER
INFECTIOUS DISEASES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
51
|
|
64
|
-20.3%
|
-20.3%
|
-
|
|
|
152
|
|
209
|
-27.3%
|
-27.3%
|
-
|
Intl
|
|
101
|
|
136
|
-25.7%
|
-26.4%
|
0.7%
|
|
|
329
|
|
426
|
-22.8%
|
-23.1%
|
0.3%
|
WW
|
|
152
|
|
200
|
-24.0%
|
-24.5%
|
0.5%
|
|
|
481
|
|
635
|
-24.3%
|
-24.5%
|
0.2%
|
See footnotes at end
of schedule
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
%
Change
|
|
|
2017
|
|
2016
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2017
|
|
2016
|
Reported
|
Operational
(1)
|
Currency
|
NEUROSCIENCE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
647
|
|
622
|
4.0%
|
4.0%
|
-
|
|
|
1,931
|
|
1,997
|
-3.3%
|
-3.3%
|
-
|
Intl
|
|
851
|
|
842
|
1.1%
|
0.6%
|
0.5%
|
|
|
2,531
|
|
2,618
|
-3.3%
|
-2.2%
|
-1.1%
|
WW
|
|
1,498
|
|
1,464
|
2.3%
|
2.0%
|
0.3%
|
|
|
4,462
|
|
4,615
|
-3.3%
|
-2.7%
|
-0.6%
|
CONCERTA /
METHYLPHENIDATE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
100
|
|
102
|
-2.0%
|
-2.0%
|
-
|
|
|
284
|
|
365
|
-22.2%
|
-22.2%
|
-
|
Intl
|
|
98
|
|
88
|
11.4%
|
10.5%
|
0.9%
|
|
|
304
|
|
294
|
3.4%
|
4.1%
|
-0.7%
|
WW
|
|
198
|
|
190
|
4.2%
|
3.8%
|
0.4%
|
|
|
588
|
|
659
|
-10.8%
|
-10.5%
|
-0.3%
|
INVEGA
SUSTENNA / XEPLION / TRINZA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
395
|
|
339
|
16.5%
|
16.5%
|
-
|
|
|
1,154
|
|
983
|
17.4%
|
17.4%
|
-
|
Intl
|
|
248
|
|
217
|
14.3%
|
11.0%
|
3.3%
|
|
|
722
|
|
646
|
11.8%
|
12.8%
|
-1.0%
|
WW
|
|
643
|
|
556
|
15.6%
|
14.3%
|
1.3%
|
|
|
1,876
|
|
1,629
|
15.2%
|
15.6%
|
-0.4%
|
RISPERDAL
CONSTA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
87
|
|
94
|
-7.4%
|
-7.4%
|
-
|
|
|
273
|
|
289
|
-5.5%
|
-5.5%
|
-
|
Intl
|
|
107
|
|
128
|
-16.4%
|
-18.0%
|
1.6%
|
|
|
335
|
|
394
|
-15.0%
|
-14.0%
|
-1.0%
|
WW
|
|
194
|
|
222
|
-12.6%
|
-13.5%
|
0.9%
|
|
|
608
|
|
683
|
-11.0%
|
-10.4%
|
-0.6%
|
OTHER
NEUROSCIENCE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
65
|
|
87
|
-25.3%
|
-25.3%
|
-
|
|
|
220
|
|
360
|
-38.9%
|
-38.9%
|
-
|
Intl
|
|
398
|
|
409
|
-2.7%
|
-1.4%
|
-1.3%
|
|
|
1,170
|
|
1,284
|
-8.9%
|
-7.7%
|
-1.2%
|
WW
|
|
463
|
|
496
|
-6.7%
|
-5.6%
|
-1.1%
|
|
|
1,390
|
|
1,644
|
-15.5%
|
-14.5%
|
-1.0%
|
ONCOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
846
|
|
622
|
36.0%
|
36.0%
|
-
|
|
|
2,207
|
|
1,740
|
26.8%
|
26.8%
|
-
|
Intl
|
|
1,052
|
|
895
|
17.5%
|
15.2%
|
2.3%
|
|
|
3,012
|
|
2,605
|
15.6%
|
16.8%
|
-1.2%
|
WW
|
|
1,898
|
|
1,517
|
25.1%
|
23.8%
|
1.3%
|
|
|
5,219
|
|
4,345
|
20.1%
|
20.8%
|
-0.7%
|
DARZALEX
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
230
|
|
124
|
85.5%
|
85.5%
|
-
|
|
|
643
|
|
320
|
*
|
*
|
-
|
Intl
|
|
87
|
|
39
|
*
|
*
|
*
|
|
|
228
|
|
52
|
*
|
*
|
*
|
WW
|
|
317
|
|
163
|
94.5%
|
92.0%
|
2.5%
|
|
|
871
|
|
372
|
*
|
*
|
*
|
IMBRUVICA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
230
|
|
179
|
28.5%
|
28.5%
|
-
|
|
|
622
|
|
455
|
36.7%
|
36.7%
|
-
|
Intl
|
|
282
|
|
170
|
65.9%
|
61.8%
|
4.1%
|
|
|
749
|
|
450
|
66.4%
|
67.7%
|
-1.3%
|
WW
|
|
512
|
|
349
|
46.7%
|
44.7%
|
2.0%
|
|
|
1,371
|
|
905
|
51.5%
|
52.1%
|
-0.6%
|
VELCADE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
-
|
-
|
-
|
-
|
Intl
|
|
273
|
|
304
|
-10.2%
|
-11.2%
|
1.0%
|
|
|
843
|
|
950
|
-11.3%
|
-9.8%
|
-1.5%
|
WW
|
|
273
|
|
304
|
-10.2%
|
-11.2%
|
1.0%
|
|
|
843
|
|
950
|
-11.3%
|
-9.8%
|
-1.5%
|
ZYTIGA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
352
|
|
282
|
24.8%
|
24.8%
|
-
|
|
|
826
|
|
840
|
-1.7%
|
-1.7%
|
-
|
Intl
|
|
317
|
|
300
|
5.7%
|
4.4%
|
1.3%
|
|
|
924
|
|
901
|
2.6%
|
3.5%
|
-0.9%
|
WW
|
|
669
|
|
582
|
14.9%
|
14.2%
|
0.7%
|
|
|
1,750
|
|
1,741
|
0.5%
|
1.0%
|
-0.5%
|
OTHER
ONCOLOGY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
34
|
|
37
|
-8.1%
|
-8.1%
|
-
|
|
|
116
|
|
125
|
-7.2%
|
-7.2%
|
-
|
Intl
|
|
93
|
|
82
|
13.4%
|
11.1%
|
2.3%
|
|
|
268
|
|
252
|
6.3%
|
7.3%
|
-1.0%
|
WW
|
|
127
|
|
119
|
6.7%
|
5.1%
|
1.6%
|
|
|
384
|
|
377
|
1.9%
|
2.6%
|
-0.7%
|
PULMONARY
HYPERTENSION(5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
387
|
|
-
|
*
|
*
|
-
|
|
|
427
|
|
-
|
*
|
*
|
-
|
Intl
|
|
283
|
|
-
|
*
|
*
|
-
|
|
|
334
|
|
-
|
*
|
*
|
-
|
WW
|
|
670
|
|
-
|
*
|
*
|
-
|
|
|
761
|
|
-
|
*
|
*
|
-
|
OPSUMIT
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
150
|
|
-
|
*
|
*
|
-
|
|
|
174
|
|
-
|
*
|
*
|
-
|
Intl
|
|
109
|
|
-
|
*
|
*
|
-
|
|
|
130
|
|
-
|
*
|
*
|
-
|
WW
|
|
259
|
|
-
|
*
|
*
|
-
|
|
|
304
|
|
-
|
*
|
*
|
-
|
TRACLEER
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
83
|
|
-
|
*
|
*
|
-
|
|
|
85
|
|
-
|
*
|
*
|
-
|
Intl
|
|
127
|
|
-
|
*
|
*
|
-
|
|
|
151
|
|
-
|
*
|
*
|
-
|
WW
|
|
210
|
|
-
|
*
|
*
|
-
|
|
|
236
|
|
-
|
*
|
*
|
-
|
UPTRAVI
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
113
|
|
-
|
*
|
*
|
-
|
|
|
121
|
|
-
|
*
|
*
|
-
|
Intl
|
|
11
|
|
-
|
*
|
*
|
-
|
|
|
12
|
|
-
|
*
|
*
|
-
|
WW
|
|
124
|
|
-
|
*
|
*
|
-
|
|
|
133
|
|
-
|
*
|
*
|
-
|
OTHER
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
41
|
|
-
|
*
|
*
|
-
|
|
|
47
|
|
-
|
*
|
*
|
-
|
Intl
|
|
36
|
|
-
|
*
|
*
|
-
|
|
|
41
|
|
-
|
*
|
*
|
-
|
WW
|
|
77
|
|
-
|
*
|
*
|
-
|
|
|
88
|
|
-
|
*
|
*
|
-
|
CARDIOVASCULAR /
METABOLISM / OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,163
|
|
1,117
|
4.1%
|
4.1%
|
-
|
|
|
3,469
|
|
3,590
|
-3.4%
|
-3.4%
|
-
|
Intl
|
|
384
|
|
376
|
2.1%
|
1.0%
|
1.1%
|
|
|
1,152
|
|
1,203
|
-4.2%
|
-2.2%
|
-2.0%
|
WW
|
|
1,547
|
|
1,493
|
3.6%
|
3.3%
|
0.3%
|
|
|
4,621
|
|
4,793
|
-3.6%
|
-3.1%
|
-0.5%
|
XARELTO
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
635
|
|
529
|
20.0%
|
20.0%
|
-
|
|
|
1,790
|
|
1,690
|
5.9%
|
5.9%
|
-
|
Intl
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
-
|
-
|
-
|
-
|
WW
|
|
635
|
|
529
|
20.0%
|
20.0%
|
-
|
|
|
1,790
|
|
1,690
|
5.9%
|
5.9%
|
-
|
INVOKANA /
INVOKAMET
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
220
|
|
294
|
-25.2%
|
-25.2%
|
-
|
|
|
723
|
|
939
|
-23.0%
|
-23.0%
|
-
|
Intl
|
|
45
|
|
34
|
32.4%
|
31.6%
|
0.8%
|
|
|
121
|
|
97
|
24.7%
|
26.5%
|
-1.8%
|
WW
|
|
265
|
|
328
|
-19.2%
|
-19.3%
|
0.1%
|
|
|
844
|
|
1,036
|
-18.5%
|
-18.3%
|
-0.2%
|
PROCRIT /
EPREX
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
168
|
|
168
|
0.0%
|
0.0%
|
-
|
|
|
511
|
|
581
|
-12.0%
|
-12.0%
|
-
|
Intl
|
|
70
|
|
82
|
-14.6%
|
-17.6%
|
3.0%
|
|
|
229
|
|
265
|
-13.6%
|
-13.3%
|
-0.3%
|
WW
|
|
238
|
|
250
|
-4.8%
|
-5.8%
|
1.0%
|
|
|
740
|
|
846
|
-12.5%
|
-12.4%
|
-0.1%
|
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
140
|
|
126
|
11.1%
|
11.1%
|
-
|
|
|
445
|
|
380
|
17.1%
|
17.1%
|
-
|
Intl
|
|
269
|
|
260
|
3.5%
|
2.9%
|
0.6%
|
|
|
802
|
|
841
|
-4.6%
|
-2.1%
|
-2.5%
|
WW
|
|
409
|
|
386
|
6.0%
|
5.6%
|
0.4%
|
|
|
1,247
|
|
1,221
|
2.1%
|
3.8%
|
-1.7%
|
TOTAL
PHARMACEUTICAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
5,816
|
|
5,042
|
15.4%
|
15.4%
|
-
|
|
|
15,698
|
|
15,123
|
3.8%
|
3.8%
|
-
|
Intl
|
|
3,879
|
|
3,358
|
15.5%
|
13.5%
|
2.0%
|
|
|
10,877
|
|
10,109
|
7.6%
|
8.4%
|
-0.8%
|
WW
|
|
$
9,695
|
|
8,400
|
15.4%
|
14.6%
|
0.8%
|
|
|
$
26,575
|
|
25,232
|
5.3%
|
5.6%
|
-0.3%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
See footnotes at end
of schedule
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REPORTED SALES vs.
PRIOR PERIOD ($MM)
|
|
THIRD
QUARTER
|
|
NINE
MONTHS
|
|
|
|
|
|
%
Change
|
|
|
|
|
|
|
|
%
Change
|
|
|
MEDICAL DEVICES
SEGMENT (2)
|
|
2017
|
|
2016
|
Reported
|
Operational
(1)
|
Currency
|
|
|
2017
|
|
2016
|
Reported
|
Operational
(1)
|
Currency
|
CARDIOVASCULAR
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
$
261
|
|
235
|
11.1%
|
11.1%
|
-
|
|
|
$
785
|
|
701
|
12.0%
|
12.0%
|
-
|
Intl
|
|
245
|
|
216
|
13.4%
|
13.9%
|
-0.5%
|
|
|
743
|
|
663
|
12.1%
|
13.5%
|
-1.4%
|
WW
|
|
506
|
|
451
|
12.2%
|
12.5%
|
-0.3%
|
|
|
1,528
|
|
1,364
|
12.0%
|
12.7%
|
-0.7%
|
DIABETES
CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
168
|
|
191
|
-12.0%
|
-12.0%
|
-
|
|
|
482
|
|
548
|
-12.0%
|
-12.0%
|
-
|
Intl
|
|
237
|
|
236
|
0.4%
|
-2.6%
|
3.0%
|
|
|
743
|
|
779
|
-4.6%
|
-4.6%
|
0.0%
|
WW
|
|
405
|
|
427
|
-5.2%
|
-6.9%
|
1.7%
|
|
|
1,225
|
|
1,327
|
-7.7%
|
-7.7%
|
0.0%
|
DIAGNOSTICS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
-
|
|
-
|
-
|
-
|
-
|
|
|
-
|
|
-
|
-
|
-
|
-
|
Intl
|
|
-
|
|
7
|
*
|
*
|
*
|
|
|
1
|
|
66
|
*
|
*
|
*
|
WW
|
|
-
|
|
7
|
*
|
*
|
*
|
|
|
1
|
|
66
|
*
|
*
|
*
|
ORTHOPAEDICS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,326
|
|
1,343
|
-1.3%
|
-1.3%
|
-
|
|
|
4,092
|
|
4,099
|
-0.2%
|
-0.2%
|
-
|
Intl
|
|
925
|
|
908
|
1.9%
|
0.0%
|
1.9%
|
|
|
2,827
|
|
2,848
|
-0.7%
|
-0.2%
|
-0.5%
|
WW
|
|
2,251
|
|
2,251
|
0.0%
|
-0.8%
|
0.8%
|
|
|
6,919
|
|
6,947
|
-0.4%
|
-0.2%
|
-0.2%
|
HIPS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
195
|
|
190
|
2.6%
|
2.6%
|
-
|
|
|
612
|
|
590
|
3.7%
|
3.7%
|
-
|
Intl
|
|
133
|
|
130
|
2.3%
|
-0.1%
|
2.4%
|
|
|
418
|
|
421
|
-0.7%
|
-0.1%
|
-0.6%
|
WW
|
|
328
|
|
320
|
2.5%
|
1.5%
|
1.0%
|
|
|
1,030
|
|
1,011
|
1.9%
|
2.2%
|
-0.3%
|
KNEES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
220
|
|
223
|
-1.3%
|
-1.3%
|
-
|
|
|
702
|
|
696
|
0.9%
|
0.9%
|
-
|
Intl
|
|
123
|
|
132
|
-6.8%
|
-9.5%
|
2.7%
|
|
|
424
|
|
433
|
-2.1%
|
-1.4%
|
-0.7%
|
WW
|
|
343
|
|
355
|
-3.4%
|
-4.4%
|
1.0%
|
|
|
1,126
|
|
1,129
|
-0.3%
|
0.0%
|
-0.3%
|
TRAUMA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
398
|
|
389
|
2.3%
|
2.3%
|
-
|
|
|
1,179
|
|
1,151
|
2.4%
|
2.4%
|
-
|
Intl
|
|
264
|
|
248
|
6.5%
|
4.6%
|
1.9%
|
|
|
768
|
|
764
|
0.5%
|
0.8%
|
-0.3%
|
WW
|
|
662
|
|
637
|
3.9%
|
3.1%
|
0.8%
|
|
|
1,947
|
|
1,915
|
1.7%
|
1.8%
|
-0.1%
|
SPINE &
OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
513
|
|
541
|
-5.2%
|
-5.2%
|
-
|
|
|
1,599
|
|
1,662
|
-3.8%
|
-3.8%
|
-
|
Intl
|
|
405
|
|
398
|
1.8%
|
0.3%
|
1.5%
|
|
|
1,217
|
|
1,230
|
-1.1%
|
-0.5%
|
-0.6%
|
WW
|
|
918
|
|
939
|
-2.2%
|
-2.8%
|
0.6%
|
|
|
2,816
|
|
2,892
|
-2.6%
|
-2.3%
|
-0.3%
|
SURGERY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
1,002
|
|
1,002
|
0.0%
|
0.0%
|
-
|
|
|
3,009
|
|
3,003
|
0.2%
|
0.2%
|
-
|
Intl
|
|
1,344
|
|
1,282
|
4.8%
|
3.7%
|
1.1%
|
|
|
3,992
|
|
3,906
|
2.2%
|
2.9%
|
-0.7%
|
WW
|
|
2,346
|
|
2,284
|
2.7%
|
2.1%
|
0.6%
|
|
|
7,001
|
|
6,909
|
1.3%
|
1.7%
|
-0.4%
|
ADVANCED
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
398
|
|
390
|
2.1%
|
2.1%
|
-
|
|
|
1,190
|
|
1,131
|
5.2%
|
5.2%
|
-
|
Intl
|
|
525
|
|
494
|
6.3%
|
5.3%
|
1.0%
|
|
|
1,543
|
|
1,478
|
4.4%
|
5.4%
|
-1.0%
|
WW
|
|
923
|
|
884
|
4.4%
|
3.9%
|
0.5%
|
|
|
2,733
|
|
2,609
|
4.8%
|
5.3%
|
-0.5%
|
GENERAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
430
|
|
414
|
3.9%
|
3.9%
|
-
|
|
|
1,276
|
|
1,254
|
1.8%
|
1.8%
|
-
|
Intl
|
|
675
|
|
649
|
4.0%
|
2.8%
|
1.2%
|
|
|
2,017
|
|
2,006
|
0.5%
|
1.1%
|
-0.6%
|
WW
|
|
1,105
|
|
1,063
|
4.0%
|
3.2%
|
0.8%
|
|
|
3,293
|
|
3,260
|
1.0%
|
1.4%
|
-0.4%
|
SPECIALTY
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
174
|
|
198
|
-12.1%
|
-12.1%
|
-
|
|
|
543
|
|
618
|
-12.1%
|
-12.1%
|
-
|
Intl
|
|
144
|
|
139
|
3.6%
|
2.8%
|
0.8%
|
|
|
432
|
|
422
|
2.4%
|
2.1%
|
0.3%
|
WW
|
|
318
|
|
337
|
-5.6%
|
-5.9%
|
0.3%
|
|
|
975
|
|
1,040
|
-6.3%
|
-6.4%
|
0.1%
|
VISION
CARE
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
432
|
|
277
|
56.0%
|
56.0%
|
-
|
|
|
1,142
|
|
767
|
48.9%
|
48.9%
|
-
|
Intl
|
|
659
|
|
462
|
42.6%
|
43.9%
|
-1.3%
|
|
|
1,802
|
|
1,297
|
38.9%
|
39.8%
|
-0.9%
|
WW
|
|
1,091
|
|
739
|
47.6%
|
48.4%
|
-0.8%
|
|
|
2,944
|
|
2,064
|
42.6%
|
43.2%
|
-0.6%
|
CONTACT LENSES
/ OTHER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
302
|
|
277
|
9.0%
|
9.0%
|
-
|
|
|
832
|
|
767
|
8.5%
|
8.5%
|
-
|
Intl
|
|
498
|
|
462
|
7.8%
|
9.1%
|
-1.3%
|
|
|
1,404
|
|
1,297
|
8.2%
|
9.1%
|
-0.9%
|
WW
|
|
800
|
|
739
|
8.3%
|
9.1%
|
-0.8%
|
|
|
2,236
|
|
2,064
|
8.3%
|
8.9%
|
-0.6%
|
SURGICAL
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
130
|
|
-
|
*
|
*
|
-
|
|
|
310
|
|
-
|
*
|
*
|
-
|
Intl
|
|
161
|
|
-
|
*
|
*
|
-
|
|
|
398
|
|
-
|
*
|
*
|
-
|
WW
|
|
291
|
|
-
|
*
|
*
|
-
|
|
|
708
|
|
-
|
*
|
*
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL MEDICAL
DEVICES
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
US
|
|
3,189
|
|
3,048
|
4.6%
|
4.6%
|
-
|
|
|
9,510
|
|
9,118
|
4.3%
|
4.3%
|
-
|
Intl
|
|
3,410
|
|
3,111
|
9.6%
|
8.6%
|
1.0%
|
|
|
10,108
|
|
9,559
|
5.7%
|
6.3%
|
-0.6%
|
WW
|
|
$
6,599
|
|
6,159
|
7.1%
|
6.6%
|
0.5%
|
|
|
$
19,618
|
|
18,677
|
5.0%
|
5.3%
|
-0.3%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* Percentage greater
than 100% or not meaningful
|
|
|
|
|
|
|
|
|
|
|
|
(1) Operational
growth excludes the effect of translational currency
|
|
|
|
|
|
|
|
|
|
|
|
(2)
Unaudited
|
|
|
|
|
|
|
|
|
|
|
|
(3) Prior year
amounts have been reclassified to conform to current year product
disclosure
|
|
|
|
|
|
|
|
|
|
|
|
(4) Reported as U.S.
sales
|
|
|
|
|
|
|
|
|
|
|
|
(5) Actelion
acquisition completed June 16, 2017
|
|
|
|
|
|
|
|
|
|
|
|
View original content with
multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2017-third-quarter-results-300537777.html
SOURCE Johnson & Johnson